Findings

What do systematic reviews say?

11 questions · 11 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 63.6%GRADE not reported 1 · 9.1%Very low 2 · 18.2%Low 1 · 9.1%Moderate 0 · 0%High 0 · 0%

Hypertonic saline 7% vs hypertonic saline

All‐cause mortality · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs rhDNase with

All‐cause mortality · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs amiloride

All‐cause mortality · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

All‐cause mortality · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs mannitol

All‐cause mortality · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 3% to 7% vs Normal saline

All‐cause mortality · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 142 participants
Low

Hypertonic saline 3% to 7% vs Normal saline

All‐cause mortality · adults and children with cystic fibrosis (stable lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs Normal saline

All‐cause mortality · people with bronchiectasis

1 finding from 1 review

Inhaled hyperosmolar agents for bronchiectasis 2014 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 113 participants
GRADE not reported

Hypertonic saline 7% vs xylitol

All‐cause mortality · adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs other intracranial pressure‐lowering agents

Mortality at 6 months · people with acute traumatic brain injury

It is very uncertain whether hypertonic saline changes mortality at 6 months compared with other intracranial pressure‐lowering agents (very low certainty).

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
RR 0.84 [0.46, 1.55]
2 studies · 85 participants
Very low

Hypertonic saline vs other intracranial pressure‐lowering agents

Mortality (short‐term) · people with acute traumatic brain injury

It is very uncertain whether hypertonic saline changes mortality (short‐term) compared with other intracranial pressure‐lowering agents (very low certainty).

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
RR 0.33
2 studies · 70 participants
Very low